KOREA UNITED PHARM. INC. COMPANY PROFILE
Overseas Business Dept. February, 2017
Contents
About KUP R&D Product (IMD, Oncology, BE approved)
Global Reference
For The Best Global Pharmaceutical Company
2
ABOUT KUP
For The Best Global Pharmaceutical Company
3
Brief Introduction
Establishment Date Business Activities
Dec. 03, 1987 Manufacture, Marketing & Sales Distribution of Pharmaceuticals and Other Healthcare Products Annual Turnover U$ 137,814,292 (2014) * Export sales - U$200million (2014) Total Assets U$ 194,952,013 (as of Dec. 31, 2014) Total Employees 1,000 employees (2016) No. of Produced Items About 300 items - *IMD, Oncology, Antibiotics, Healthcare Supplements & Foods, OTC Drugs (including Vitamins & Korean Ginseng products) Exporting countries Over 42 countries *IMD : Incrementally Modified Drug(≒Super generic)
For The Best Global Pharmaceutical Company
4
Brief Introduction â–ś Sejong 1 Factory Solid formulation including various IMDs has been actively producing. As the factory only for general injectable which complies to cGMP and EU-GMP has been completely constructed. Injectables are available for export markets.
Sejong 2 Factory Has been completely transformed to the factory specialized in Anti-cancer drug in 2013. From the 2015, the company is preparing for introducing cutting-edge facility and equipment aiming at cGMP approval.
For The Best Global Pharmaceutical Company
5
Brief Introduction New Oncology Factory (Under Construction) 2016Y No
1
2017Y
2018Y
Schedule
Design Layout
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
2
Select constructor
3
Construction
4
Eligibility
5
Manufacturing Facility Transfer
6
Pilot Production
7
GMP Accredit
8
Commercial Production
For The Best Global Pharmaceutical Company
6
Research & Development
For The Best Global Pharmaceutical Company
7
Domestic Leader, IMD
√ IMD specialized
√ 13% for R&D Investment
For The Best Global Pharmaceutical Company
8
Long Term Plan Currency Unit: US Dollar
IMD rate 43%
164 Mil.
IMD rate 15%
103 Mil.
113 Mil.
125 Mil.
182 Mil.
145 Mil.
GENERIC 105 Mil. 111 Mil.
111 Mil. 103 Mil.
106 Mil. 77 Mil.
97 Mil.
IMD
53 Mil. 34 Mil. 5.7 Mil.
10 Mil.
2013
2014
20.3 Mil.
2015
2016
2017
For The Best Global Pharmaceutical Company
2018 9
Product Pipe-line
For The Best Global Pharmaceutical Company
10
PRODUCT
For The Best Global Pharmaceutical Company
11
Recent Data Leading Causes Of Death (Global) Ischaemic heart disease Stroke Lower respiratory infection Chronic obstructive pulmonary disease Diarrhoeal diseases HIV/AIDS Trachea, bronchus, lung cancers Diabetes mellitus Road injury Hypertensive heart disease Pre-term birth complications Liver cirrhosis Tuberculosis Kidney diseases Self-harm Liver cancer Stomach cancer Birth asphyxia and birth trauma Colon and rectum cancers Falls Alzheimer's and other dementias Breast cancer
With rising incidence of chronic diseases and cancers, the global mortality profile will shift toward non-communicable diseases by 2030
2015 Rank 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 - -
2030 Rank 1 2 4 3 9 8 6 5 7 10 19 11 - 13 16 12 14 - 15 17 18 20
Distribution of Deaths by Cause, Global, 2015 and 2030
2015
57 million deaths
68.4%
2030
70 million deaths
73.9%
Noncommunicable Diseases
Noncommunicable Diseases
Communicable Diseases
Communicable Diseases
Injuries
Injuries
Future Outlook Future healthcare delivery will focus on personalized medicine that revolves around a more customized model of care.
Source: Causes of Death 2015 and 2030 WHO), Frost & Sullivan
For The Best Global Pharmaceutical Company
12
KUP Product
Incrementally Modified Drugs
Anti platelet agent Cilostan CR Tab. INGREDIENT / STRENGTH INDICATION
Cilostazol 200mg Ischemic symptoms, Prevention of stroke, Cerebral infarction
Anti platelet agent Clavixin Duo Cap. INGREDIENT / STRENGTH INDICATION
Clopidogrel 75 mg + Aspirin 100 mg Atherothrombotic event, Myocardial Infarction, Acute coronary syndrome, Stroke
For The Best Global Pharmaceutical Company
13
KUP Product
Incrementally Modified Drugs
NSAIDs Clanza CR Tab. INGREDIENT / STRENGTH INDICATION
Aceclofenac 200mg Chronic Musculoskeletal Pain (Rheumatoid arthritis, Ankylosing spondylitis, Osteoarthritis etc)
Acute Bronchitis Kalomin Tab. INGREDIENT / STRENGTH INDICATION
Pelargonium sidoides 11%, Ethanol Extract 1235.52mg Acute bronchitis
For The Best Global Pharmaceutical Company
14
KUP Product
Oncology Drugs
Antibiotic Anti-cancer
Anti-Metabolite agents Epizin Inj. Gemtabin Inj.
Gemcitabine HCl
200mg, 1g, 2g
Xeltabine Tab.
Capecitabine
500mg
Pemirex Inj.
Pemetrexed
100mg, 300mg, 500mg
Microtubule Inhibitors Newtaxel –A Inj. Unitaxel Inj.
Docetaxel Paclitaxel
10mg, 50mg
Alkylating agents Platinox Inj.
Oxaliplatin
50mg
Topoisomerase Inhibitors Topocan Inj.
Topotecan HCl
4mg, 10mg
Targeting Anti-Cancer
20mg, 80mg 30mg, 100mg, 150mg
Epirubicin HCl
Erlotib Tab.
Erlotinib HCl
150mg
Glotib Tab.
Imatinib mesylate
100mg, 400mg
For The Best Global Pharmaceutical Company
15
KUP Product
Prescription & OTC Drugs
Gastrointestinal system Cardiovascular & Hematopoietic system Respiratory system Central Nervous system Musculo- Skeletal system Endocrine & Metabolic system Anti-Infectives Allergy&Immune system Gentio-Urinary system X-RAY Contrast medium Antidotes Vitamines & Minerals & Nutrition For The Best Global Pharmaceutical Company
16
Global Reference
For The Best Global Pharmaceutical Company
17
Global Network & Partners Global Partners
■ Production site (Local & Global) ■ Branch office (Current) ■ Branch office (Future) ■
Uzbekistan
■
China
■
■
■
Iran
■■
Philippines
Vietnam
■
Colombia
Malaysia
■ ■ ■
■
Ecuador
Myanmar ■
Korea
Thailand ■
Indonesia
Peru
For The Best Global Pharmaceutical Company
18
THANK YOU FOR YOUR ATTENTION